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Background: Germany has a low tuberculosis (TB) inci-
dence. A relevant and increasing proportion of TB cases 
is diagnosed among asylum seekers upon screen-
ing. Aim: We aimed to assess whether cases identified 
by screening asylum seekers had equally successful 
and completely reported treatment outcomes as cases 
diagnosed by passive case finding and contact trac-
ing in the general population.  Methods:  We analysed 
characteristics and treatment outcomes of pulmonary 
TB cases notified in Germany between 2002 and 2014, 
stratified by mode of case finding. We performed 
three multivariable analyses with different dependent 
variables: Model A: successful vs all other outcomes, 
Model B: successful vs documented non-successful 
clinical outcome and Model C: known outcome vs lost 
to follow-up. Results: TB treatment success was high-
est among cases identified by contact tracing (87%; 
3,139/3,591), followed by passive case finding (74%; 
28,804/39,019) and by screening asylum seekers 
(60%; 884/1,474). Cases identified by screening asy-
lum seekers had 2.4 times higher odds of not having a 
successful treatment outcome as opposed to all other 
outcomes (A), 1.4 times higher odds of not having a 
successful treatment outcome as opposed to known 
non-successful outcomes (B) and 2.3 times higher 
odds of loss to follow-up (C) than cases identified by 
passive case finding.  Conclusion:  Screened asylum 
seekers had poorer treatment outcomes and were 
more often lost to follow-up. Linking patients to treat-
ment facilities and investigating potential barriers to 
treatment completion are needed to secure screening 
benefits for asylum seekers and communities.
Introduction 
With 10.4 million new cases of active tuberculosis (TB) 
in 2016, TB remains one of the world’s biggest health 
threats [1]. Most countries in the European Union (EU) 
are low-incidence countries where TB predominantly 
affects vulnerable populations such as migrants, pris-
oners and people living with HIV [2]. To achieve an 
ongoing decrease in TB incidence in EU countries, fur-
ther efforts are needed to address these often hard-
to-reach groups [2]. In Germany, 5,915 cases of active 
TB were notified in 2016 [3]. Demographic changes and 
migration influence TB incidence in Germany and con-
tributed to the end of a previously declining TB trend 
[3,4]. Ensuring early detection and comprehensive 
access of all population groups to timely and complete 
treatment will be essential to control TB and ultimately 
meet the World Health Organization’s (WHO) TB elimi-
nation goals [5].
Cases found by passive case finding, i.e. TB patients 
diagnosed after clinical presentation with symptoms 
or post mortem, contributed the highest proportion of 
new cases in 2016 (66%) [3]. Sixteen per cent of cases 
had been diagnosed by active case finding among asy-
lum seekers and refugees [3]. This proportion was on 
average 2.4% between 2002 and 2014 and had been 
increasing since 2008, when it was smallest (0.7%) [3]. 
Active case finding is performed among several risk 
groups to ensure early detection and treatment and to 
prevent further transmission from infectious cases. In 
recently exposed persons, contact tracing is performed 
according to German contact tracing recommendations 
[6]. Among asylum seekers, screening is performed to 
find infectious pulmonary TB cases early at admission 
to shared accommodations (reception centres) after 
entering the country. Screening for infectious pulmo-
nary TB at entry to such shared accommodations is 
mandatory according to §36.4 of the Protection Against 
Infection Act (Infektionsschutzgesetz (IfSG)). With 
the increasing number of migrants seeking asylum 
in Germany, the mandatory screening for infectious 
pulmonary TB among asylum seekers has challenged 
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local public health authorities (LPHA) in 2014 and 2015 
[7-11].
TB diagnosis – upon screening or clinical presenta-
tion – needs to be followed by rapid initiation of an 
effective and complete treatment to prevent further 
transmission, achieve cure and prevent the develop-
ment of secondary drug resistance [12]. Tuberculosis 
treatment outcome monitoring is an essential part of 
TB surveillance and key for evaluating the effective-
ness of TB screening and care. In line with international 
requirements [1,2], the German TB notification system 
comprises the treatment outcome categories  cured, 
treatment completed, died, treatment failure, treat-
ment default, still on treatment, transfer out, miss-
ing  and  unable to determine  (Table 1). Treatment 
outcome is measured after 12 months follow-up and 
after 24 months for multidrug-resistant TB (MDR-TB) 
cases. The WHO and the Stop TB Partnership set the 
target of 90% treatment success (i.e. cured and treat-
ment completed) for all TB cases that require treatment 
[1,13].
To what extent pulmonary TB found among screened 
asylum seekers in Germany is followed up until treat-
ment completion, remains unclear however. We 
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Possible TB treatment outcomes in the German national surveillance data   
Group B: Treatment success vs no treatment success (only cases with known outcome)




























































Group A: Treatment success vs all other outcomes (according to ECDC definition 2016 [2]).
Success (coded 0)
Success (coded 0)
Known outcome (coded 0) Loss to follow-up (coded 1)
All other outcomes (coded 1) 
No treatment success (coded 1) Excluded from analysis, outcome unknown 
(coded “missing“)
ECDC: European Centre for Disease Prevention and Control; TB: tuberculosis.
a Still on treatment is regarded as loss to follow-up when disease onset is more than 24 months ago for non-MDR-TB or more than 36 months 
ago for MDR-TB, the remaining cases are regarded as cases with known outcome.
For this study, ‘loss to follow-up’ describes cases that were ‘lost’ to the national TB notification system, i.e. the outcome cannot be evaluated. 
This should be distinguished from the newly introduced term ‘lost to follow-up’ that has replaced ‘defaulter’ in international TB reports and 
describes a known treatment interruption for at least two consecutive months.
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therefore aimed to assess whether TB cases identified 
by screening among asylum seekers had an equally 
successful and completely reported treatment outcome 
as those diagnosed by passive case finding and by 
contact tracing, in order to highlight potential gaps in 
surveillance and case management.
Methods 
Data source
We used case-based national TB notification data from 
Germany, reported to the Robert Koch Institute (RKI) 
through the electronic reporting system SurvNet@RKI 
[14]. Date of data extraction was 1 March 2016.
We included in our analysis pulmonary TB cases noti-
fied between 2002 and 2014 with available informa-
tion on age and sex (total n = 52,995). The dataset was 
further restricted to cases that were identified by the 
following modes of case finding: (i) screening of asy-
lum seekers, (ii) passive case finding and (iii) contact 
tracing (total n = 44,084). The notification system, 
case definitions for TB and diagnostic procedures have 
remained largely unchanged over the investigation 
period.
Definitions
For German national disease surveillance, a case of 
TB is defined by clinical diagnosis of TB by a physi-
cian followed by the decision to initiate a full course 
of anti-tuberculosis treatment, with or without bac-
teriological confirmation or epidemiological link 
[15]. Bacteriological confirmation refers to a cul-
ture of  Mycobacterium tuberculosis  complex, or a 
combination of a positive microscopy result for acid-
fast bacilli with a positive nucleic acid amplification 
test (NAAT) for the same specimen type [15]. In the TB 
notification system, information on the patients’ age, 
sex, country of birth and the mode of case finding is 
recorded, as is bacteriological testing including drug 
resistance, previous TB diagnosis, site of TB and treat-
ment outcome at any time of follow-up, in this study 
set to at least 12 months [16].
Modes of case finding are defined by reporting guide-
lines [16]. Screened asylum seekers are defined as TB 
cases that were identified by screening asylum seek-
ers according to §36.4 IfSG by chest X-ray (except 
pregnant women or children younger than 15 years) on 
admission to a shared accommodation [17]. In children 
and pregnant women, screening including clinical signs 
Figure 2
Treatment outcomes of notified pulmonary tuberculosis cases by mode of case finding, Germany, 2002–2014 (n = 44,084)
0% 20% 40% 60% 80% 100%
Passive case finding (N=39,019)
Contact tracing (N=3,591)a
Screening asylum seekers (N=1,474)a
Cured Treatment completed Died
Treatment failure Treatment default Still on treatment
Transfer out Missing Unable to determine
a Active case finding.
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and symptoms and immunological testing with either 
interferon-γ release assay (IGRA) or tuberculin skin 
test (TST) is recommended [17,18]. Thus, the screen-
ing intended to rule out infectious pulmonary TB also 
leads to the detection of pulmonary TB with negative 
bacteriological result. Cases identified by passive 
case finding are defined as TB cases diagnosed after 
clinical presentation; TB cases diagnosed post mortem 
were excluded from our study. Cases identified during 
the follow-up of exposed persons are defined as cases 
identified by contact tracing. Cases identified by other 
active case finding were not considered in this study.
Treatment success and data completeness
To assess treatment success and data completeness, 
we grouped treatment outcomes in three different ways 
(Group A, B and C) as displayed in Figure 1. 
Group A: Cases that were cured or had treatment com-
pleted were referred to as cases with successful treat-
ment and compared with cases that were recorded with 
all other outcomes. This definition is adapted from 
ECDC classification 2016 [2] and is in line with WHO 
and the Stop TB Partnership’s definitions of treatment 
outcomes [1,13].
Group B: Cases with successful treatment were com-
pared with cases with known non-successful treatment 
outcomes (died, treatment failure or default); all cases 
with outcome categories that contained essentially no 
information on the result of the treatment of the case 
(still on treatment, transfer out, missing and unable to 
determine) were excluded from this comparison in order 
to disentangle cases with non-successful treatment 
outcome from cases that were lost to follow-up.
Group C: Cases with known treatment outcomes, 
both successful and unsuccessful  (successful treat-
ment, died, treatment failure, treatment default)  were 
compared with cases that were lost to follow-up to the 
national tuberculosis notification system (transfer out, 
missing, unable to determine or too long still on treat-
ment). The classification is based on the assumption 
that in all these cases, LPHA did presumably not have 
up-to-date information and could not ascertain the 
treatment outcome. ‘Too long’  still on treatment  was 
defined as cases without MDR-TB who were notified 
as  still on treatment more than 24 months after notifi-
cation and MDR-TB cases who were notified as still on 
treatment more than 36 months after notification. The 
remaining cases notified as  still on treatment  were 
defined as cases with known outcome as still on treat-
ment is valid information on the treatment status.
Data analysis and protection
We describe demographic information, i.e. age (contin-
uous), sex (female vs male), country of birth (Germany 
vs WHO regions excluding Germany vs unknown), 
as well as clinical information, i.e. MDR (not applica-
ble, no drug susceptibility test (DST) reported, DST 
reported and among those with DST: not MDR vs MDR), 
previous TB diagnosis (no vs yes vs unknown), infec-
tiousness (respiratory specimen: culture-negative and 
smear-negative vs culture-positive and smear-negative 
vs smear-positive vs unknown), severity of disease 
(pulmonary TB with TB of the central nervous system 
(CNS), meningitis or disseminated TB vs pulmonary 
TB only or with other secondary sites vs pulmonary TB 
with unknown additional manifestations) and treat-
ment outcomes (Figure 1) by mode of case finding.
We also describe the above characteristics by treat-
ment outcome. For categorical variables, we present 
numbers and proportions, for continuous variables, 
median and interquartile range (IQR).
The associations between mode of case finding 
and treatment outcome or loss to follow-up were 
Table 1
Tuberculosis treatment outcome categories in the national notification system, Germany, 2002–2014
Categories Definitions
Cured Treatment completed and culture-negative samples taken at the end of the full course treatment and on at least one previous occasion
Treatment 
completed
Treatment completed without evidence of failure but no tests were performed or no result was available at the end of 
the full course of treatment
Died Death before cure or treatment completion, irrespective of cause
Treatment failure Culture or sputum smear remaining positive or becoming positive again 5 months or more into the course of treatment
Treatment defaulta Treatment interrupted for at least 2 consecutive months
Still on treatment Patient still on treatment at 12 months (and at 24 months for multidrug-resistant (MDR) TB cases) without any other outcome during treatment
Transfer out Patient referred to a known or unknown address and information on outcome not available
Missing Information on treatment outcome is missing (empty field)
Unable to 
determine Information on treatment outcome could not be obtained by the local public health authority
a‘Treatment default’ is the translation of the German category name ‘Abbruch der Behandlung’. Internationally, the previously used term 
‘defaulter’ has recently been replaced by ‘lost to follow-up’, but this is not reflected in the German TB surveillance system.
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investigated with multivariable logistic regression 
analyses using the passive case finding group as ref-
erence group. We interpreted coefficients in terms of 
odds ratios (OR) and report 95% confidence intervals 
(CI). We designed three logistic regression models (A, 
B, C) with different dependent variables: one for each 
group (A, B, C) of treatment outcome and loss to fol-
low-up (Figure 1). We included mode of case finding as 
the independent variable and the following potential 
confounders (as described above if not specified) in all 
three models: age (in groups of 15 years), sex, coun-
try of birth (simplified: Germany vs other vs unknown), 
drug resistance (simplified: not MDR, MDR, unknown), 
infectiousness, previous TB and severity of disease, 
as well as reporting period (2002–05 vs 2006–14) as 
changes in data plausibility checks and completeness 
checks were introduced in 2006.
Analyses were conducted with STATA version 14 (Stata 
corporation, Texas, United States).
Table 2
Demographic and clinical characteristics of pulmonary tuberculosis cases notified by mode of case finding, Germany, 
2002–2014 (n = 44,084)
Characteristics of cases
Active case finding Passive case finding
Screening asylum seekers Contact tracing
Diagnosis 
subsequent to clinical 
presentation
N = 1,474 N = 3,591 N = 39,019
n % of N N % of N n % of N
Demographic characteristics
Median age in years (IQR) 28 (22-37) 27 (11-44) 50 (34-68)
Sex
Female 336 23 1,628 45 14,373 37
Male 1,138 77 1,963 55 24,646 63
Place of birth
Germany 6 0.4 2,312 64 21,420 55
Other country
WHO Region Europe without Germany 539 37 773 21 10,156 26
WHO Region Eastern Mediterranean 377 26 104 2.9 1,682 4.3
WHO Region Africa 320 22 84 2.3 1,722 4.4
WHO Region South-East Asia 46 3.1 74 2.1 1,345 3.4
WHO Region Western Pacific 82 5.6 58 1.6 997 2.6
WHO Region Americas 4 0.3 11 0.3 266 0.7
Unknown country 100 6.8 175 4.9 1,431 3.7
Clinical characteristics
Infectiousness
Culture-negative, smear-negative 496 34 1,164 32 6,268 16
Culture-positive, smear-negative 498 34 1,417 39 12,737 33
Smear-positive 410 28 748 21 18,966 49
Unknown 70 4.7 262 7.3 1,048 2.7
Previous TB
No 876 59 3,252 91 29,963 77
Yes 201 14 109 3.0 4,429 11
Unknown 397 27 230 6.4 4,627 12
Drug resistance
Drug susceptibility test (DST reported) 838 57 2,037 57 28,950 74
Not MDR (% of DST reported) 747 89 2,004 98 28,388 98
MDR (% of DST reported) 91 11 33 1.6 562 1.9
Unknown
Not applicable; bacteriologically negative 486 33 1,129 31 6,075 16
No drug susceptibility test reported 150 10 425 12 3,994 10
Severity of disease
Exclusively pulmonary TB 1,173 80 3,081 86 32,620 84
Pulmonary and CNS, meningitis or disseminated TB 5 0.3 10 0.3 574 1.5
Unknown 296 20 500 15 5,825 15
CNS: central nervous system; DST: drug susceptibility test; MDR: multidrug-resistant; TB: tuberculosis; WHO: World Health Organization.
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Table 3
Demographic and clinical characteristics of notified pulmonary tuberculosis cases by treatment outcome, Germany, 
2002–2014 (n = 44,084)
Characteristics of cases
Group A: successful 
outcomes (n) among all 
outcomes (N)
Group B: successful 
outcomes (n) among known 
outcomes (N)
Group C: known outcomes 
(n) among all outcomes (N)





Main exposure of interest
Mode of case finding
Passive case finding 28,804 39,019 74 28,804 34,766 83 35,214 39,019 90
Contact tracing 3,139 3,591 87 3,139 3,285 96 3,334 3,591 93
Screening asylum seekers 884 1,474 60 884 983 90 1,062 1,474 72
Demographic characteristics
Age in years
< 15 1,611 1,782 90 1,611 1,634 99 1,654 1,782 93
15–29 6,329 7,874 80 6,329 6,645 95 6,777 7,874 86
30–44 8,256 10,322 80 8,256 8,959 92 9,105 10,322 88
45–59 7,536 9,674 78 7,536 8,652 87 8,769 9,674 91
60–74 5,649 8,070 70 5,649 7,342 77 7,432 8,070 92
≥ 75 3,446 6,362 54 3,446 5,802 59 5,873 6,362 92
Sex
Female 12,699 16,337 78 12,699 14,557 87 14,761 16,337 90
Male 20,128 27,747 73 20,128 24,477 82 24,849 27,747 90
Place of birth
Germany 17,337 23,738 73 17,337 21,653 80 21,950 23,738 92
Other 
country
WHO Region Europe 8,850 11,468 77 8,850 10,077 88 10,192 11,468 89
WHO Region Eastern Mediterranean 1,701 2,163 79 1,701 1,848 92 1,892 2,163 87
WHO Region Africa 1,675 2,126 79 1,675 1,794 93 1,819 2,126 86
WHO Region South-East Asia 1,141 1,465 78 1,141 1,233 93 1,252 1,465 85
WHO Region Western Pacific 886 1,137 78 886 955 93 970 1,137 85
WHO Region Americas 232 281 83 232 244 95 248 281 88
Unknown country 1,005 1,706 59 1,005 1,230 82 1,287 1,706 75
Clinical characteristics
Infectiousness
Culture-negative, smear-negative 6,128 7,928 77 6,128 7,118 86 7,288 7,928 92
Culture-positive, smear-negative 11,035 14,652 75 11,035 13,089 84 13,212 14,652 90
Smear-positive 14,806 20,124 74 14,806 17,750 83 17,984 20,124 89
Unknown 858 1,380 62 858 1,077 80 1,126 1,380 82
Previous TB
No 26,433 34,091 77 26,433 30,690 86 31,090 34,091 91
Yes 3,188 4,739 67 3,188 4,132 77 4,193 4,739 88
Unknown 3,206 5,254 61 3,206 4,212 76 4,327 5,254 82
Drug resistance
Not MDR 24,034 31,139 77 24,034 28,066 86 28,214 31,139 91
MDR 399 686 58 399 505 79 536 686 78
Unknown
Not applicable; bacteriologically 
negative 5,963 7,690 77 5,963 6,930 86 7,089 7,690 92
No drug susceptibility test reported 2,431 4,569 53 2,431 3,533 69 3,762 4,569 82
Severity of disease
Exclusively pulmonary TB 28,163 36,874 76 28,163 33,114 85 33,583 36,874 91
Pulmonary and CNS, meningitis or disseminated TB 342 589 58 342 520 66 527 589 89
Unknown 4,322 6,621 65 4,322 5,400 80 5,500 6,621 83
Time period based on change of data plausibility and completeness checks
2002–05 12,594 17,310 73 12,594 14,978 84 15,251 17,310 88
2006–14 20,233 26,774 76 20,233 24,056 84 24,359 26,774 91
CNS: central nervous system; DST: drug susceptibility test; MDR: multidrug-resistant; TB: tuberculosis; WHO: World Health Organization.
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Table 4
Notified pulmonary tuberculosis cases - multivariable analyses for the association between the mode of case finding and 
treatment outcome, Germany, 2002–2014 (n = 44,084)
Characteristics of cases
Model A: success  
 
(0) vs all other outcomes (1)
Model B: success  
 
(0) vs no treatment success (1)
Model C: known outcome  
 
(0) vs loss to follow-up (1)
aOR 95% CI p value aOR 95% CI p value aOR 95% CI p value
Main exposure of interest
Mode of case finding
Passive case finding Ref Ref Ref
Contact tracing 0.64 0.57–0.71 < 0.001 0.54 0.45–0.65 < 0.001 0.73 0.63–0.84 < 0.001
Screening asylum seekers 2.37 2.11–2.67 < 0.001 1.38 1.10–1.73 0.006 2.35 2.06–2.68 < 0.001
Demographic characteristics
Age in years
< 15 Ref Ref Ref
15–29 1.84 1.54–2.20 < 0.001 3.06 1.98–4.73 < 0.001 1.41 1.15–1.74 < 0.001
30–44 1.90 1.59–2.26 < 0.001 4.79 3.13–7.34 < 0.001 1.25 1.02–1.54 0.030
45–59 2.11 1.77–2.51 < 0.001 7.43 4.86–11.35 < 0.001 1.06 0.86–1.30 0.571
60–74 3.09 2.59–3.68 < 0.001 14.53 9.52–22.19 < 0.001 0.84 0.68–1.04 0.116
≥ 75 6.39 5.35–7.63 < 0.001 34.15 22.36–52.16 < 0.001 0.82 0.66–1.02 0.081
Sex
Female Ref Ref Ref
Male 1.33 1.26–1.39 < 0.001 1.52 1.42–1.62 < 0.001 1.07 1.00–1.14 0.049
Place of birth
Germany Ref Ref Ref
Other country 0.90 0.85–0.94 < 0.001 0.70 0.65–0.75 < 0.001 1.34 1.25–1.45 < 0.001
Unknown country 1.81 1.61–2.03 < 0.001 0.94 0.80–1.12 0.494 3.10 2.72–3.53 < 0.001
Clinical characteristics
Infectiousness
Culture-negative, smear-negative Ref Ref Ref
Culture-positive, smear-negative 2.58 2.35–2.84 < 0.001 2.35 2.08–2.65 < 0.001 2.19 1.91–2.50 < 0.001
Smear-positive 2.79 2.55–3.05 < 0.001 2.54 2.27–2.85 < 0.001 2.31 2.04–2.62 < 0.001
Unknown 2.12 1.86–2.41 < 0.001 1.64 1.37–1.97 < 0.001 2.43 2.06–2.87 < 0.001
Previous TB treatment
No Ref Ref Ref
Yes 1.20 1.12–1.29 < 0.001 1.18 1.08–1.28 < 0.001 1.23 1.11–1.36 0.003
Unknown 1.90 1.78–2.03 < 0.001 1.84 1.69–1.97 < 0.001 1.73 1.59–1.88 < 0.001
Drug resistance
No MDR Ref Ref Ref
MDR 2.83 2.40–3.32 < 0.001 3.03 2.40–3.83 < 0.001 1.89 1.56–2.30 < 0.001
Unknown 2.76 2.56–2.98 < 0.001 2.56 2.33–2.81 < 0.001 1.83 1.65–2.02 < 0.001
Severity of disease
Exclusively pulmonary TB Ref Ref Ref
Pulmonary and CNS, meningitis or 
disseminated TB 2.51 2.10–2.99 < 0.001 3.25 2.63–4.00 < 0.001 1.23 0.94–1.62 0.125
Unknown 1.48 1.40–1.58 < 0.001 1.24 1.15–1.35 < 0.001 1.83 1.70–1.98 < 0.001
Time period based on change of data plausibility and completeness checks
2002–05 Ref Ref Ref
2006–14 0.91 0.86–0.95 < 0.001 1.04 0.98–1.10 0.228 0.75 0.70–0.80 < 0.001
aOR: adjusted odds ratio; CI: confidence interval; CNS: central nervous system; MDR: multidrug-resistant; TB: tuberculosis.
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All investigated data were anonymous and collected 
within the legal framework of the IfSG.
Results 
The cases’ demographic and clinical characteris-
tics stratified by mode of case finding are presented 
in Table 2.
Cases identified by screening asylum seekers 
(n = 1,474) were of similar median age with a smaller 
IQR compared with cases identified by contact tracing 
(n = 3,591) (28 vs 27 years) and were less often female 
(23% vs 45%). They had a similar proportion of cul-
ture- and smear-negative cases (34% vs 32%), more 
often unknown information about previous TB (27% vs 
6.4%) and more often MDR-TB (11% vs 1.6%) (Table 2). 
Compared with cases identified by passive case find-
ing (n = 39,019), the cases identified by screening asy-
lum seekers had a lower median age (28 vs 50 years), a 
lower proportion of females (23% vs 37%) and a higher 
proportion of culture- and smear-negative cases (34% 
vs 16%), of unknown information about previous TB 
(27% vs 12%) and of MDR-TB (11% vs 1.9%) (Table 2).
Treatment success was highest among pulmonary TB 
cases identified by contact tracing (87%; 3,139/3,591), 
followed by cases identified by passive case finding 
(74%; 28,804/39,019) and by screening asylum seek-
ers (60%; 884/1,474) (Figure 2).
The largest proportion of missing and indeterminate 
data on treatment outcome was among cases identi-
fied by screening asylum seekers (22%; 329/1,474), 
followed by patients identified by passive case find-
ing (7.9%; 3,076/39,019) and contact tracing (6.3%; 
225/3,591) (Figure 2).
Detailed analyses showed that the proportion of suc-
cessful outcomes among all outcomes (Group A, Figure 
1) varied not only by the mode of case finding but also 
by age, sex, place of birth, infectiousness, previous TB 
diagnosis treatment, drug resistance, severity of dis-
ease and changes in data plausibility and complete-
ness checks (Table 3).
Treatment success (Group A) was particularly low among 
TB cases who had no DST reported (53%; 2,431/4,569), 
were 75 years or older (54%; 3,446/6,362), had MDR-TB 
(58%; 399/686), a severe TB manifestation (CNS, 
meningitis or disseminated) in addition to pulmonary 
TB (58%; 342/589), unknown place of birth (59%; 
1,005/1,706) or were identified by screening asylum 
seekers (60%; 884/1,474) (Table 3).
Analysis adjusted for demographic and clinical charac-
teristics showed that mode of case finding was inde-
pendently associated with treatment success (Model 
A, Figure 1, Table 4). It indicated 2.4 times higher odds 
of non-successful treatment for cases identified by 
screening asylum seekers compared with cases iden-
tified by passive case finding; cases identified by 
contact tracing showed 0.64 times lower odds of non-
successful treatment outcomes compared with passive 
case finding (Table 4).
Restricting analysis of treatment outcomes to cases 
with known outcomes (Group B,  Figure 1) and com-
paring successful and non-successful treatment 
among them, treatment success was particularly low 
for cases  aged 75 years or older (59%; 3,446/5,802), 
with severe manifestation in addition to pulmonary TB 
(66%; 342/520) and cases that had no DST reported 
(69%; 2,431/3,533) (Table 3). While cases identified by 
screening asylum seekers had higher treatment suc-
cess (90%; 884/983) than cases identified by passive 
case finding (83%; 28,804/34,766) in the descriptive 
analysis of Group B, adjusted analysis indicated 1.4 
times higher odds for a non-successful treatment out-
come for cases identified by screening asylum seekers 
compared with cases identified by passive case find-
ing (Model B, Table 4). In addition, older age, MDR-TB, 
severe manifestations and infectiousness were associ-
ated with particularly high odds of unsuccessful treat-
ment outcome in Model B (Table 4).
Analysis of loss to follow-up (Group C) showed that 
the proportion of known outcomes among all possible 
treatment outcomes was lowest among cases identi-
fied by screening asylum seekers (72%; 1,062/1,474), 
followed by cases with unknown place of birth (75%; 
1,287/1,706) and cases with MDR (78%; 536/686) 
(Table 3). Adjusted analysis indicated 2.3 times higher 
odds for loss to follow-up among cases identified by 
screening asylum seekers compared with cases identi-
fied by passive case finding; cases identified by con-
tact tracing showed 27% lower odds of loss to follow-up 
compared with passive case finding (Model C, Table 4). 
Apart from identification by screening asylum seekers, 
cases with unknown place of birth and unknown drug 
resistance showed particularly high odds of getting 
lost to follow-up (Table 4).
Discussion 
With our study, we aimed to assess treatment outcomes 
of pulmonary TB cases identified by screening asylum 
seekers. We found that cases identified by screening 
asylum seekers – unlike cases identified by contact 
tracing – had significantly poorer treatment outcomes 
and higher odds of loss to follow-up compared with 
cases identified by passive case finding after adjust-
ment for demographic and clinical characteristics.
Cases identified by screening asylum seekers were 
similar to those identified by contact tracing in terms 
of age, infectiousness and severity of disease but were 
more likely to have MDR-TB or a history of previous TB 
diagnosis. Compared with cases identified by passive 
case finding, those among screened asylum seekers 
were younger, more often male and less infectious.
Our study results corroborate previous findings that TB 
screening by chest X-ray, as used for asylum seekers, 
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allowed early detection of cases that were still smear-
negative [19-22]. Thus screening has the potential to 
prevent transmission and facilitate early treatment 
initiation. The high proportion of bacteriologically 
negative pulmonary TB cases (34%) raises the issue 
of potential overdiagnosis of TB by chest X-ray screen-
ing. However, TB cases identified by contact tracing 
were equally often bacteriologically negative, and the 
detection of bacteriologically negative TB is considered 
beneficial given the high risk of developing infectious 
TB if untreated [23]. In addition, screened asylum seek-
ers were more likely to have had a diagnosis of MDR-TB 
or a positive or unknown history of previous TB com-
pared with cases identified by passive case finding. 
Contributing factors may include higher rates of TB 
and MDR-TB in their country of birth [1] and fragmented 
healthcare services in countries of origin leading to 
treatment interruptions [24]. Of note, DST results, 
which are strongly warranted for treatment decisions, 
were frequently unavailable.
With 60% treatment success (Group A) among pulmo-
nary TB cases identified by screening asylum seekers, 
74% among those identified by passive case finding 
and 87% among those identified by contact tracing, 
none of the groups met the target of 90% treatment 
success [1,13]. However, the odds for non-successful 
treatment were substantially higher for cases identi-
fied by screening asylum seekers and markedly lower 
for cases identified by contact tracing compared to the 
cases identified by passive case finding (adjusted for 
other known confounders).
While asylum seeker status was independently associ-
ated with an unsuccessful treatment outcome, this was 
not true for reporting a foreign country of birth, which 
had lower odds of non-successful treatment outcomes 
(Model A). Other studies also found poorer treatment 
adherence for migrants with insecure legal status [25] 
and those that had arrived recently [26], but did not 
find an independent negative impact of foreign country 
of origin. Our findings contrast with a recent analysis of 
European data that found poorer treatment outcomes 
for foreign-born cases; however, that study could not 
distinguish between legal status and country of birth 
[27].
The magnitude of association between known clinical 
risk factors and non-successful treatment outcomes 
was greater when unknown outcomes were excluded 
from the analysis (Model B). In accordance with previ-
ous knowledge [20,27,28], increasing age, a proxy for 
co-morbidities and risk of dying, strongly increased the 
odds of non-successful treatment in model B. In addi-
tion, the odds for MDR-TB and severe disease mani-
festations were greater among those with negative 
treatment outcomes in model B compared with model 
A, in coherence with previous studies [20,29-32].
In our study, being identified by screening asylum 
seekers was also independently associated with being 
lost to follow-up after adjustment for potential con-
founders. Reasons for loss to follow-up can include the 
patient’s decision to stop treatment without informing 
treatment facilities [33]. A potential explanation for 
this may be the lack of perceived illness [34] that might 
be more pronounced in cases identified by screening 
who had no symptoms. That patients identified by con-
tact tracing were 27% less likely to be lost to follow-up 
than patients identified by passive case finding, how-
ever, indicates that even asymptomatic patients can 
be successfully followed up. Geographical distance to 
TB-treatment facilities, a trusting and supportive pro-
vider–patient relationship as well as security of legal 
status have been found to be predictors for treatment 
adherence [25,34-36]. The reduction of structural barri-
ers to TB diagnosis and treatment including availabil-
ity of free, accessible and culturally appropriate health 
services for vulnerable groups such as migrants has 
been shown to be a key element in increasing treat-
ment success [36]. Potential structural barriers to TB 
treatment completion and reasons for loss to follow-up 
in Germany include limited access to care and inter-
preters [7], (forced) relocations of asylum seekers 
within Germany or to other countries during treatment 
[7,11,33] and changing administrative authorities han-
dling the case [10].
Limitations
Our investigation was based on national notification 
data, and under- or overestimation of the true case 
number owing to under-diagnosis and under-reporting 
or to double-reporting cannot be entirely excluded. In 
addition, incomplete information for notified cases at 
the national level may reflect unavailable data at the 
treatment facility or at the LPHA level. Non-reported 
treatment outcome cannot entirely be disentangled 
from non-completed treatment in our data. The TB 
patient may have completed treatment within the 
remit of a different health authority than the one that 
received the initial notification, or under the supervi-
sion of a doctor or hospital that has missed to report 
the treatment outcome to the local health authority.
Based on the available variables in the notification 
data, our analysis could only compare ‘asylum seekers 
identified by screening’ with cases identified by other 
modes of case finding. However, cases identified by 
other modes of case finding may also be asylum seek-
ers. Furthermore, incorrect classification of the mode 
of case finding cannot be excluded.
Full information on tuberculosis treatment outcome 
becomes available only 1 year after the reporting year 
and our study therefore includes cases notified up to 
and including 2014. Whether characteristics and treat-
ment outcomes of cases notified from 2002 to 2014 can 
be extrapolated to cases notified later is unknown and 
will require evaluation. Increasing workload at LPHA 
level caused by increasing case numbers (by nearly 




The low proportion of smear-positive TB suggests that 
asylum seekers were found early by screening; a good 
starting point for successful treatment. However, they 
were often lost to follow-up and had poorer treatment 
outcomes than cases identified by passive case find-
ing or contact tracing.
The documentation of mode of case finding in German 
TB notification data proved useful for the evalua-
tion of group-specific treatment outcomes, namely 
screened asylum seekers. We recommend a standard-
ised approach to reporting of case finding information 
across Europe to allow evaluation of treatment success 
and comparison across countries by modes of case 
finding. Regarding treatment outcome data, we need to 
better disentangle non-reported treatment outcomes 
from reporting incomplete course of treatment and to 
address both issues individually to obtain high treat-
ment success.
Increased case detection by screening can only unfold 
its health benefits when detected tuberculosis is effec-
tively treated and reliably cured. Tuberculosis screen-
ing activities among asylum seekers can be a door to 
access general medical care. TB screening at admis-
sion to reception centres may also reduce TB exposure 
and reduce the need for resource-intensive contact 
investigations in these settings.
While specific reasons for the higher odds of non-suc-
cessful treatment among asylum seekers in Germany 
need to be studied further, available research suggests 
that patients need to be better linked to treatment 
facilities and structural barriers to treatment comple-
tion need to be addressed to secure screening benefits 
for asylum seekers and the communities.
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